(Top) Event-free survival (EFS) of HCL patients treated with cladribine according to the presence (M) or the absence (UM) of IGHV somatic mutations. (Bottom) Progression-free survival (A) and overall survival (C) in patients with respect to the use of VH4-34 gene.